Charmacy Pharmaceutical Co., Ltd.
Symboli: 2289.HK
HKSE
10.6
HKDMarkkinahinta tänään
26.5108
P/E-suhde
-0.6536
PEG-suhde
1.14B
MRK Cap
- 0.08%
DIV Tuotto
Charmacy Pharmaceutical Co., Ltd. (2289-HK) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2048.73 | 634.2 | 503.8 | 641.8 | |||||||||||
balance-sheet.row.short-term-investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.net-receivables | 3455.49 | 965.4 | 865.3 | 731.3 | |||||||||||
balance-sheet.row.inventory | 2642.09 | 775.8 | 586.9 | 509.2 | |||||||||||
balance-sheet.row.other-current-assets | 1683.13 | 436.6 | 506.4 | 356 | |||||||||||
balance-sheet.row.total-current-assets | 9829.44 | 2812 | 2462.4 | 2238.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 1267.58 | 328.5 | 294.1 | 348.4 | |||||||||||
balance-sheet.row.goodwill | 24.1 | 6 | 6 | 6 | |||||||||||
balance-sheet.row.intangible-assets | 376.24 | 76.7 | 80.9 | 143 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 400.34 | 82.7 | 86.9 | 149.1 | |||||||||||
balance-sheet.row.long-term-investments | 1234.74 | 0 | 374.7 | 489.3 | |||||||||||
balance-sheet.row.tax-assets | 29.25 | 7.4 | 6.2 | 8.2 | |||||||||||
balance-sheet.row.other-non-current-assets | -1239.64 | 17 | -381 | -497.5 | |||||||||||
balance-sheet.row.total-non-current-assets | 1692.27 | 435.7 | 381 | 497.5 | |||||||||||
balance-sheet.row.other-assets | 71.28 | 0 | 22.6 | 27.4 | |||||||||||
balance-sheet.row.total-assets | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.account-payables | 3709.65 | 659.1 | 876.8 | 809.8 | |||||||||||
balance-sheet.row.short-term-debt | 5654.1 | 1531.1 | 1390 | 1512.6 | |||||||||||
balance-sheet.row.tax-payables | 296.21 | 56 | 94.2 | 44.6 | |||||||||||
balance-sheet.row.long-term-debt-total | 131.02 | 30.4 | 15.8 | 86.9 | |||||||||||
Deferred Revenue Non Current | -1.37 | -0.6 | 0 | 0.3 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.52 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 3492.36 | 2.5 | 1378.8 | 1349.2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 132.52 | 31 | 15.8 | 86.9 | |||||||||||
balance-sheet.row.other-liabilities | 11.38 | 0 | 0 | 13.2 | |||||||||||
balance-sheet.row.capital-lease-obligations | 84.83 | 37 | 15.8 | 15.5 | |||||||||||
balance-sheet.row.total-liab | 9303.15 | 2649.8 | 2271.4 | 2259 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 432 | 108 | 108 | 108 | |||||||||||
balance-sheet.row.retained-earnings | 712.22 | 181.2 | 207.5 | 117.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 280.97 | 279 | 1 | 1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 864.66 | 29.7 | 278 | 278 | |||||||||||
balance-sheet.row.total-stockholders-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 11593 | - | - | - | |||||||||||
Total Investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.total-debt | 5796.4 | 1561.5 | 1405.8 | 1611.9 | |||||||||||
balance-sheet.row.net-debt | 3780.94 | 927.3 | 913.1 | 981.8 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 141.73 | 90.4 | 23.2 | 40.6 | ||||||||||
cash-flows.row.depreciation-and-amortization | 41.75 | 28.8 | 32 | 24.6 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | -404.55 | -300.2 | 20.9 | -227.9 | ||||||||||
cash-flows.row.account-receivables | -187.1 | -222.5 | -54.8 | -158 | ||||||||||
cash-flows.row.inventory | -217.45 | -77.7 | 75.8 | -69.8 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-non-cash-items | 36.34 | 225 | -95.7 | 293.8 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -184.73 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -2.9 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 160.41 | 80.4 | 0.6 | 0.1 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 121.65 | 71.8 | -24.4 | -54.8 | ||||||||||
cash-flows.row.debt-repayment | 0 | -1074.5 | -824.1 | -888.6 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | -40.42 | -28.4 | -52.5 | -56.5 | ||||||||||
cash-flows.row.other-financing-activites | 52.15 | 911.7 | 951 | 942.5 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 11.73 | -191.2 | 74.4 | -2.7 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -51.31 | -75.4 | 30.5 | 73.6 | ||||||||||
cash-flows.row.cash-at-end-of-period | 332.42 | 68.9 | 144.2 | 113.8 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 383.73 | 144.2 | 113.8 | 40.1 | ||||||||||
cash-flows.row.operating-cash-flow | -184.73 | 44.1 | -19.5 | 131.1 | ||||||||||
cash-flows.row.capital-expenditure | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.free-cash-flow | -223.5 | 35.5 | -44.6 | 79.1 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 8578.91 | 4403.6 | 4175.3 | 3793.6 | |||||||||||
income-statement-row.row.cost-of-revenue | 8017.56 | 4110.9 | 3906.7 | 3559.5 | |||||||||||
income-statement-row.row.gross-profit | 561.35 | 292.7 | 268.6 | 234.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 97.18 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.operating-expenses | 304.92 | 178 | 116.1 | 163.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 8322.48 | 4288.9 | 4022.8 | 3722.9 | |||||||||||
income-statement-row.row.interest-income | 66.96 | 4.3 | 30.5 | 37.7 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.total-operating-expenses | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 53.79 | 26.5 | 25.7 | 29.1 | |||||||||||
income-statement-row.row.ebitda-caps | 255.88 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 202.09 | 66.2 | 93.5 | 74.4 | |||||||||||
income-statement-row.row.income-before-tax | 189.47 | 67.4 | 122.1 | 33 | |||||||||||
income-statement-row.row.income-tax-expense | 47.75 | 16.1 | 31.7 | 9.8 | |||||||||||
income-statement-row.row.net-income | 141.73 | 51.3 | 90.5 | 23.2 |
Usein kysytty kysymys
Mikä on Charmacy Pharmaceutical Co., Ltd. (2289.HK) taseen loppusumma?
Charmacy Pharmaceutical Co., Ltd. (2289.HK) kokonaisvarat ovat 3247655876.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 4403633477.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.066.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -2.398.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.012.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on 0.025.
Mikä on Charmacy Pharmaceutical Co., Ltd. (2289.HK) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 51344725.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 1561459369.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 178011533.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 634197229.000.